Tags
- A
- Achievement
- Acro
- Across
- Adult
- Alway, Newport
- American College
- American College of Rheumatology
- An
- Analysis
- Ankylosing spondylitis
- Ankylosis
- Antibody
- Approval
- Approved
- Arthralgia
- Arthritis
- Assessment
- Atul Deodhar
- Axial
- Axial spondyloarthritis
- Based on
- Benefit
- CEO
- Chief
- Chief commercial officer
- Chronic
- Chronic inflammatory disease
- Clinic
- Clinical
- Clinical endpoint
- Clinical trial
- College
- Community
- Complete
- Consistency
- Cytokine
- Daily activities
- Deodhar
- Disease
- Division
- Drive
- Drug
- Dual
- Efficacy
- Endpoint
- Endpoints
- Executive
- FDA
- Few Options
- Food and Drug Administration
- Foundation
- Health
- Health impact
- Highlight
- Howard Jd
- Humanized antibody
- Immunoglobulin G
- Impact
- Impacts
- Index
- Indication
- Inflammation
- Inflammatory
- Inhibition
- Inhibitor
- Interleukin
- International
- International Society
- Investigator
- M
- Marks
- Mathematical optimization
- M.D.
- Medical
- Medical director
- Medical sign
- Medication
- Medicine
- Mobile
- Moderate
- Moderate-to-severe
- Monoclonal
- National Psoriasis Foundation
- New
- Noted
- Officer
- One Year
- Only
- Onset
- Open-label trial
- Option
- Options
- Oregon
- Pain
- Patient
- Phase
- Phase III
- Placebo
- Plaque
- Population
- Portland
- Portland, Oregon
- President Head
- Press release
- Primary
- Professor
- Professor of medicine
- PSA
- Psoriasis
- Psoriasis Area and Severity Index
- Psoriatic arthritis
- Quality
- Quality of life
- Ranking
- Rapid
- Real World
- Real-world experience
- Regulation
- Relief
- Result
- Rheumatology
- Science
- Secondary
- Secondary endpoints
- Severity
- Signs
- Some
- Spectrum
- Spondylitis
- Spondyloarthropathy
- Stiffness
- Sustain
- Symptom
- Symptoms
- Systemic
- The division
- The first
- The national
- Therapy
- These Three
- The Spectrum
- Three
- Threshold
- Thresholds
- TNF
- TNF inhibitor
- Treat
- Treatment options
- Trial
- Trials
- Two-dimensional nuclear magnetic resonance spectroscopy
- UCB
- University
- Vice president
- Welcome
- Who